Beam Q3 net loss $112.7M; cash $1.1B; BEAM-302 expands; Orbital acquisition by BMS

Beam Therapeutics Inc.

2025-Q3 EPS reported -$3.32 revenue$25,634,000

Net loss of $112.7M ($1.10 per share) in Q3 2025 vs $96.7M ($1.17 per share) in Q3 2024.
Cash, cash equivalents and marketable securities $1.1B as of Sep 30, 2025, up from $850.7M at Dec 31, 2024; runway into 2028.
BEAM-302 expanded: multi-dose cohort (60 mg x2, 8 wks apart) in Part A; first patient dosed in Part B (liver disease). Data in early 2026.
BEAM-101 updated data accepted for ASH Dec 2025; FDA granted RMAT designation in Aug 2025.
First subject dosed with BEAM-103 (ESCAPE mAb) in Phase 1 HV trial; BMS to acquire Orbital for $1.5B; Beam holds ~17% stake.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.